Endogenous Cushing's Syndrome Epidemiology Forecast 2025-2034

The endogenous Cushing’s syndrome epidemiological forecast indicates that improved detection techniques and increasing awareness of the condition are likely to contribute to higher reported incidence rates. Cushing's disease accounts for about 80% of cases of endogenous Cushing's syndrome, according to Hirsch, Dania et al. (2018) and other researchers. It is considered the most prevalent form of endogenous Cushing's syndrome, with the annual incidence estimated to range from 1 in 588,235 to 833,333 individuals, as per Orphanet.

Endogenous Cushing’s Syndrome Epidemiology Forecast Report Coverage

The “Endogenous Cushing’s Syndrome Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of endogenous Cushing’s syndrome. It projects the future incidence and prevalence rates of endogenous Cushing’s syndrome cases across various populations. The study covers age and type as major determinants of the endogenous Cushing’s syndrome population. The report highlights patterns in the prevalence of endogenous Cushing’s syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on endogenous Cushing’s syndrome epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Endogenous Cushing’s Syndrome Understanding: Disease Overview

Endogenous Cushing’s syndrome comprises a group of disorders caused by the overproduction of cortisol. When cortisol is produced in excess over an extended period, it can lead to a range of symptoms and health complications, including obesity, hypertension, diabetes, and weakened bones.

Endogenous Cushing's syndrome is due to problems within the body's own cortisol-producing system, unlike in exogenous Cushing's syndrome, which results from taking corticosteroid medications for a longer duration. Endogenous Cushing’s syndrome can be caused by Cushing’s disease, ectopic ACTH syndrome, or adrenal Cushing’s syndrome.

Endogenous Cushing’s Syndrome Epidemiology Perspective

The Endogenous Cushing’s Syndrome epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for endogenous Cushing’s syndrome epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The endogenous Cushing’s syndrome detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Excess cortisol production due to an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor is known as Cushing's disease, and it accounts for approximately 80% of cases of endogenous Cushing's syndrome, according to Hirsch, Dania et al. (2018) and other researchers.
• Cushing's disease (CD) is considered the most prevalent form of endogenous Cushing's syndrome. The annual incidence is estimated to range from 1 in 588,235 to 833,333 individuals, while the overall incidence of Cushing's syndrome (from all causes) is estimated to be between 1 in 12,658 to 17,544 individuals per year, as per Orphanet.
• The Cleveland Clinic reports that approximately 40 to 70 individuals out of 1 million each year are affected by Cushing syndrome.
• Endogenous Cushing’s syndrome occurs due to cortisol produced by the body, affecting children, teenagers, and adults. It is primarily found in people between the ages of 25 and 50. The average age at diagnosis is 40 years, with a significant predominance of cases in females.

Country-wise Endogenous Cushing’s Syndrome Epidemiology Segment

The endogenous Cushing’s syndrome epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of endogenous Cushing’s syndrome varies significantly between countries due to differences in factors such as genetic predisposition, healthcare access, diagnostic practices, environmental influences (such as exposure to toxins or certain medications), and sociocultural factors. In the United States, approximately 10 to 15 new cases per million individuals are diagnosed each year, as per the Oregon Health & Science University (OHSU).

Endogenous Cushing’s Syndrome: Treatment Overview

The treatment approach for endogenous Cushing’s syndrome is based on the underlying cause of the excess cortisol production. For Cushing’s disease, the primary treatment is surgical removal of the tumor, typically through a minimally invasive procedure called transsphenoidal surgery. In cases where the excess cortisol is produced by adrenal tumors, adrenalectomy, or surgical removal of the affected adrenal gland, is often required.

Endogenous Cushing’s syndrome therapeutics that block cortisol production, such as ketoconazole or mitotane, are used to manage symptoms in cases where surgery is not an option. For endogenous Cushing’s syndrome patients with complications like high blood pressure, diabetes, or osteoporosis, supportive treatments like antihypertensive drugs, insulin for diabetes, and bone-protective medications may also be recommended by the healthcare provider.

Key Questions Answered

• What are the key findings of endogenous Cushing’s syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with endogenous Cushing’s syndrome across the 8 major markets during the forecast period?
• What was the country-wise endogenous Cushing’s syndrome epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of endogenous Cushing’s syndrome patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of endogenous Cushing’s syndrome during the forecast period of 2025-2034?
• What are the currently available treatments in the endogenous Cushing’s syndrome market?
• What are the disease risks, signs, symptoms, and unmet needs of endogenous Cushing’s syndrome?

Scope of the Endogenous Cushing’s Syndrome Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of endogenous Cushing’s syndrome based on several factors.
• The Endogenous Cushing’s Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The endogenous Cushing’s syndrome report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.